EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry

Dominik Kiem, Michael Leisch, Ildiko Toth, Marie-Christina Mayer, Lisa Pleyer, Richard Greil, Alexander Egle, Thomas Melchardt

European Journal of Haematology · 2025

DOI: 10.1111/ejh.14445 ↗

Kurz gefasst

Fallbericht in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Dominik Kiem und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine III With Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University…. Hauptthemen laut MEDLINE: Pyrimidines, Genetic Diseases, X-Linked, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

VEXAS syndrome is caused by somatic mutations in the UBA1 gene and includes features of both autoinflammatory and myeloid diseases. Among several treatment options, JAK inhibitors have proven effective, especially ruxolitinib. However, anemia is often present in VEXAS syndrome. The novel JAK inhibitor momelotinib is approved for myelofibrosis with anemia. Here, we report of two patients within the Austrian Myeloid Registry of the Austrian Group Medical Tumor Therapy (AGMT), with newly diagnosed VEXAS syndrome and anemia, who were treated with momelotinib. Both patients experienced an improvement in anemia, a decrease in inflammation, and the treatment was well tolerated. VEXAS syndrome (acronym for: vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) is an autoinflammatory disease caused by somatic mutations in the ubiquitin‐like modifier activating enzyme 1 (UBA1) gene. Key clinical features comprise hematological as well as rheumatological, features. Associated hematological conditions include cytopenia, bone marrow failure, myelodysplastic syndrome, increased risk for thromboembolic events, and prominent vacuolization of myeloid and erythroid precursor cells in the bone marrow.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesGenetic Diseases, X-LinkedJanus Kinase InhibitorsHumansMaleRegistriesTreatment OutcomeMutationFemaleMiddle AgedUbiquitin-Activating EnzymesAustriaAnemiaAgedMyelodysplastic SyndromesSkin Diseases, Genetic

Stichwörter der Autor:innen

JAK inhibitorVEXAS syndromeautoinflammationmyelodysplastic syndrome

Substanzen

PyrimidinesUbiquitin-Activating EnzymesUBA1 protein, humanJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Internal Medicine III With Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, Salzburg, Austria.
  • Cancer Cluster Salzburg, Salzburg, Austria.
  • Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Salzburg, Austria.

Zitieren

APA

Kiem, D., Leisch, M., Toth, I., Mayer, M. C., Pleyer, L., Greil, R., Egle, A., & Melchardt, T. (2025). Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry. European Journal of Haematology. https://doi.org/10.1111/ejh.14445

Vancouver

Kiem D, Leisch M, Toth I, Mayer MC, Pleyer L, Greil R, et al. Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry. European Journal of Haematology. 2025. doi:10.1111/ejh.14445

BibTeX
@article{Kiem2025,
  author = {Kiem, Dominik and Leisch, Michael and Toth, Ildiko and Mayer, Marie-Christina and Pleyer, Lisa and Greil, Richard and Egle, Alexander and Melchardt, Thomas},
  title = {Momelotinib Is Effective in Treatment for VEXAS Syndrome: Two Cases Within the AGMT Austrian Myeloid Registry},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.14445}
}
Kostenlos starten →